Evidence map›Paper›PMID 25385345›Full record

ArticleJournal of the American Heart Association2014

Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.

Vanessa Fontana, Caitrin W McDonough, Yan Gong, Nihal M El Rouby, Ana Caroline C Sá, Kent D Taylor, Y-D Ida Chen, John G Gums, Arlene B Chapman, Stephen T Turner and 3 more

2 registry-linked trialsOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000554 phase3completednot on this map

Women's Ischemia Syndrome Evaluation (WISE)

TypeinterventionalSponsorUniversity of PittsburghRan2001 to 2007ConditionsAngina Pectoris, Cardiovascular Diseases, Coronary Disease, Heart DiseasesArmsAngiography, MRI, Dobutamine-Stress Echocardiography, PET,, Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing
NCT00133692 phase4completednot on this map

INternational VErapamil SR Trandolapril STudy

TypeinterventionalSponsorUniversity of FloridaRan1997 to 2003Enrolled22,000ConditionsHypertension, Coronary Artery DiseaseArmsVerapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Application of omics in hypertension and resistant hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Review
  11. The association ofFrontiers in genetics · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Vanessa FontanaDepartment of Pharmacology, Faculty of Medical Sciences, University of Campinas, Campinas, SP, Brazil (V.F.).
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL (C.W.M.D., Y.G., N.M.E.R., A.C.C., J.G.G., J.A.J., R.M.C.D.H.).
Yan GongDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL (C.W.M.D., Y.G., N.M.E.R., A.C.C., J.G.G., J.A.J., R.M.C.D.H.).
Nihal M El RoubyDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL (C.W.M.D., Y.G., N.M.E.R., A.C.C., J.G.G., J.A.J., R.M.C.D.H.).
Ana Caroline C SáDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL (C.W.M.D., Y.G., N.M.E.R., A.C.C., J.G.G., J.A.J., R.M.C.D.H.).
Kent D TaylorInstitute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute Harbor-UCLA Medical Center, Torrance, CA (K.D.T., I.C.).
Y-D Ida ChenInstitute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute Harbor-UCLA Medical Center, Torrance, CA (K.D.T., I.C.).
John G GumsDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL (C.W.M.D., Y.G., N.M.E.R., A.C.C., J.G.G., J.A.J., R.M.C.D.H.) Department of Community Health and Family Medicine, University of Florida College of Medicine, Gainesville, FL (J.G.G.).
Arlene B ChapmanThe Renal Division, Department of Medicine, Emory University, Atlanta, GA (A.B.C.).
Stephen T TurnerDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (S.T.T.).
Carl J PepineDivision of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL (C.J.P., J.A.J., R.M.C.D.H.).
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL (C.W.M.D., Y.G., N.M.E.R., A.C.C., J.G.G., J.A.J., R.M.C.D.H.) Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL (C.J.P., J.A.J., R.M.C.D.H.).
Rhonda M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL (C.W.M.D., Y.G., N.M.E.R., A.C.C., J.G.G., J.A.J., R.M.C.D.H.) Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL (C.J.P., J.A.J., R.M.C.D.H.).
University of Florida · USThe Lundquist Institute · USEmory University · USMayo Clinic in Arizona · USUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
Hypertension PharmacogeneticsR01HL074730 · NHLBI · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2003 to 2006
$3.4M
NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR000454NHLBI NIH HHS R01 HL074730NHLBI NIH HHS R01HL074730NIDDK NIH HHS P30 DK063491NIGMS NIH HHS U01 GM074492NIGMS NIH HHS U01-GM074492
6 · The paper itself

Abstract

backgroundResistant hypertension (RHTN), defined by lack of blood pressure (BP) control despite treatment with at least 3 antihypertensive drugs, increases cardiovascular risk compared with controlled hypertension. Yet, there are few data on genetic variants associated with RHTN. METHODS AND

resultsWe used a gene-centric array containing ≈50 000 single-nucleotide polymorphisms (SNPs) to identify polymorphisms associated with RHTN in hypertensive participants with coronary artery disease (CAD) from INVEST-GENES (the INnternational VErapamil-SR Trandolapril STudy-GENEtic Substudy). RHTN was defined as BP≥140/90 on 3 drugs, or any BP on 4 or more drugs. Logistic regression analysis was performed in European Americans (n=904) and Hispanics (n=837), using an additive model adjusted for age, gender, randomized treatment assignment, body mass index, principal components for ancestry, and other significant predictors of RHTN. Replication of the top SNP was conducted in 241 European American women from WISE (Women's Ischemia Syndrome Evaluation), where RHTN was defined similarly. To investigate the functional effect of rs12817819, mRNA expression was measured in whole blood. We found ATP2B1 rs12817819 associated with RHTN in both INVEST European Americans (P-value=2.44×10(-3), odds ratio=1.57 [1.17 to 2.01]) and INVEST Hispanics (P=7.69×10(-4), odds ratio=1.76 [1.27 to 2.44]). A consistent trend was observed at rs12817819 in WISE, and the INVEST-WISE meta-analysis result reached chip-wide significance (P=1.60×10(-6), odds ratio=1.65 [1.36 to 1.95]). Expression analyses revealed significant differences in ATP2B1 expression by rs12817819 genotype.

conclusionsThe ATP2B1 rs12817819 A allele is associated with increased risk for RHTN in hypertensive participants with documented CAD or suspected ischemic heart disease. CLINICAL TRIAL REGISTRATION URL: www.clinicaltrials.gov; Unique identifiers: NCT00133692 (INVEST), NCT00000554 (WISE).

Indexed as

Polymorphism, Single NucleotideAgedAntihypertensive AgentsBlood PressureDrug ResistanceDrug Therapy, CombinationFemaleGenetic Association StudiesGenetic MarkersGenetic Predisposition to DiseaseHispanic or LatinoHumansHypertensionLogistic ModelsMaleMiddle AgedAntihypertensive AgentsATP2B1 protein, humanGenetic MarkersPlasma Membrane Calcium-Transporting ATPasesgeneticshypertensionpharmacologyresistant hypertension

Identifiers

PMID25385345
PMCPMC4338734
OpenAlexW2163796351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.